Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00368472




Registration number
NCT00368472
Ethics application status
Date submitted
22/08/2006
Date registered
24/08/2006
Date last updated
10/12/2015

Titles & IDs
Public title
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
Scientific title
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
Secondary ID [1] 0 0
E2007-A001-207
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Epilepsy 0 0
Condition category
Condition code
Neurological 0 0 0 0
Epilepsy
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Perampanel

Experimental: Perampanel - Participants previously receiving placebo/perampanel in the double blind study, were titrated to receive perampanel 2 mg to 12 mg, once daily during the OLE study


Treatment: Drugs: Perampanel
Perampanel 2 mg to 12 mg, once daily during the OLE study
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Treatment-emergent Non-serious Adverse Events (AEs) and Treatment-emergent Serious Adverse Events (SAEs)
Timepoint [1] 0 0
From date of first dose of perampanel up to 30 days after the last dose of perampanel or up to approximately 8 years
Secondary outcome [1] 0 0
Percent Change in Seizure Frequency Per 28 Days Relative to Pre-Perampanel Baseline
Timepoint [1] 0 0
Baseline up to Week 221
Secondary outcome [2] 0 0
Percentage of Participants Who Experienced a 50% or Greater Reduction in Seizure Frequency Per 28 Days Relative to the Pre-perampanel Baseline
Timepoint [2] 0 0
Baseline up to week 221

Eligibility
Key inclusion criteria
KEY INCLUSION CRITERIA:

1. Have completed all scheduled visits up to and including Visit 8 in the E2007-A001-206
(NCT00144690) study or Visit 9 of the E2007-G000-208 (NCT00416195) study.

2. Are reliable and willing to make themselves available for the study period and are
able to record seizures and report adverse events themselves or have a caregiver who
can record and report the events.

3. Females of childbearing potential must continue practicing a medically acceptable
method of contraception (e.g., abstinence, a barrier method plus spermicide, or
Intrauterine device (IUD)) and for 8 weeks after the end of the OLE study. Those women
using hormonal contraceptives must also continue using an additional approved method
of contraception (e.g., a barrier method plus spermicide, or IUD).

4. Are between the ages of 18 and 70 years of age, inclusive.

5. Are at least 40 kg (88 lb) of weight.

6. Are currently being treated with a stable dose of one, or a maximum of three licensed
Anti-epileptic drugs (AEDs) and are known to take their medication(s) as directed.

KEY EXCLUSION CRITERIA:

1. Show evidence of clinically significant disease (cardiac, respiratory,
gastrointestinal, renal disease, etc.,) that, in the opinion of the Investigator(s),
could affect the participant's safety or trial conduct.

2. Show evidence of significant active hepatic disease and/or bilirubin greater than 1.5
mg/dL. Stable elevations of liver enzymes, alanine aminotransferase (ALT), and
aspartate aminotransferase (AST) due to concomitant medication(s) will be allowed if
they are less than two times the upper limit of normal (ULN).

3. Show evidence of significant active hematological disease. White blood cell (WBC)
count cannot be less than or equal to 2500/microL or an absolute neutrophil count less
than or equal to 1000/microL.

4. Clinically significant ECG abnormality, including prolonged QTc (defined as greater
than or equal to 450 msec).

5. Presence of major active psychiatric disease. Participants taking a stable dose of
selective serotonin reuptake inhibitor (SSRI) antidepressant will be allowed.
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2014
Sample size
Target
Accrual to date
Final
138
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA
Recruitment hospital [1] 0 0
- Chatswood
Recruitment hospital [2] 0 0
- Maroochydore
Recruitment hospital [3] 0 0
- Woodville
Recruitment postcode(s) [1] 0 0
2067 - Chatswood
Recruitment postcode(s) [2] 0 0
4558 - Maroochydore
Recruitment postcode(s) [3] 0 0
5011 - Woodville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Utah
Country [11] 0 0
United States of America
State/province [11] 0 0
Vermont
Country [12] 0 0
Belgium
State/province [12] 0 0
Edegem
Country [13] 0 0
Belgium
State/province [13] 0 0
Gent
Country [14] 0 0
Belgium
State/province [14] 0 0
Leuven
Country [15] 0 0
Belgium
State/province [15] 0 0
Tielt
Country [16] 0 0
Czech Republic
State/province [16] 0 0
Brno
Country [17] 0 0
Czech Republic
State/province [17] 0 0
Hradec Kralove
Country [18] 0 0
Czech Republic
State/province [18] 0 0
Olomouc
Country [19] 0 0
Czech Republic
State/province [19] 0 0
Ostrava
Country [20] 0 0
Czech Republic
State/province [20] 0 0
Praha 5
Country [21] 0 0
Czech Republic
State/province [21] 0 0
Rychnov nad Kneznou
Country [22] 0 0
Estonia
State/province [22] 0 0
Tallinn
Country [23] 0 0
Estonia
State/province [23] 0 0
Tartu
Country [24] 0 0
Finland
State/province [24] 0 0
Kuopio
Country [25] 0 0
Finland
State/province [25] 0 0
Tampere
Country [26] 0 0
France
State/province [26] 0 0
Lille
Country [27] 0 0
France
State/province [27] 0 0
Montpellier
Country [28] 0 0
France
State/province [28] 0 0
Ramonville Saint-Agne
Country [29] 0 0
Germany
State/province [29] 0 0
Berlin
Country [30] 0 0
Germany
State/province [30] 0 0
Gottingen
Country [31] 0 0
Germany
State/province [31] 0 0
Munchen
Country [32] 0 0
Germany
State/province [32] 0 0
Ulm
Country [33] 0 0
Latvia
State/province [33] 0 0
Riga
Country [34] 0 0
Lithuania
State/province [34] 0 0
Kaunas
Country [35] 0 0
Lithuania
State/province [35] 0 0
Klaipeda
Country [36] 0 0
Lithuania
State/province [36] 0 0
Siauliai
Country [37] 0 0
Lithuania
State/province [37] 0 0
Vilnius
Country [38] 0 0
Netherlands
State/province [38] 0 0
Rotterdam
Country [39] 0 0
Spain
State/province [39] 0 0
Valencia
Country [40] 0 0
Sweden
State/province [40] 0 0
Stockholm
Country [41] 0 0
United Kingdom
State/province [41] 0 0
Dundee

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eisai Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine the safety of perampanel given as adjunctive,
long-term treatment in patients with refractory partial onset seizures.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00368472
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00368472